ClinicalTrials.gg
CompletedNCT03315936Updated Mar 18, 2024Results posted

This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated

A Phase 1 interventional study of BI 894416 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This first-in man trial is designed to investigate the safety and tolerability of BI 894416 in healthy male subjects following oral administration of single rising doses.

Pharmacokinetics (PK) including dose proportionality after single dosing of BI 894416 as oral solution will be explored, the investigation of PK of BI 894416 as tablet formulation and the exploration of relative bioavailability of BI 894416 as tablet formulation compared to oral solution.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)),12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 45 years (incl.)
  • (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or (ECG) and including the neurological examination) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. /QTc interval prolongation)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on specified trial days
  • Alcohol abuse (consumption of more than 30 g per day)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

In addition, the following trial-specific exclusion criteria apply:

  • History of relevant neurological disorder affecting the peripheral or central nervous system (this includes, but is not limited to: stroke, epilepsy, inflammatory or atrophic diseases affecting the nervous system, cluster headache or any cancer of the nervous system)
  • History of immunological disease except allergy not relevant to the trial (such as mild hay fever or dust mite allergy) and except asthma in childhood or adolescence
  • History of cancer (other than successfully treated basal cell carcinoma)
  • Within 10 days prior to administration of trial medication, use of any drug that could reasonably inhibit aggregation or coagulation (e.g., acetylsalicylic acid)
  • Male subjects with woman of child bearing potential () partner who are unwilling to use male (condom or sexual abstinence) from time point of administration of trial medication until 30 days thereafter.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
68 participants (actual)

Study arms

  • Placebo comparator
    Placebo matching BI 894416 (SRD Part)

    Single Rising Dose (SRD) Part

    Drug: Placebo

  • Experimental
    BI 894416 3 milligram (mg)

    SRD Part

    Drug: BI 894416

  • Experimental
    BI 894416 10 mg

    SRD Part

    Drug: BI 894416

  • Experimental
    BI 894416 20 mg

    SRD Part

    Drug: BI 894416

  • Experimental
    BI 894416 30 mg

    SRD Part

    Drug: BI 894416

  • Experimental
    BI 894416 40 mg

    SRD Part

    Drug: BI 894416

  • Experimental
    BI 894416 54 mg

    SRD Part

    Drug: BI 894416

  • Experimental
    BI 894416 70 mg

    SRD Part

    Drug: BI 894416

  • Experimental
    BI 894416 10mg tb / 10mg PfOS / 40mg tb

    BI 894416 10 mg tablet (tb) / BI 894416 10 mg powder for oral solution (PfOS) / BI 894416 4\*10 mg tablets. Relative bioavailability (rel BA) part

    Drug: BI 894416

  • Experimental
    BI 894416 10mg PfOS / 10mg tb / 40mg tb

    BI 894416 10 mg powder for oral solution (PfOS) / BI 894416 10 mg tablet (tb) / BI 894416 4\*10 mg tablets. Relative bioavailability (rel BA) part.

    Drug: BI 894416

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Drug-related Adverse Events in SRD Part

    Percentage of participants with drug-related adverse events (AEs) in SRD part. Percentages are calculated using total number of subjects per treatment as the denominator. Percentages were rounded up to 1 decimal places.

    Time frame: From drug administration until end of the trial, up to 17 days.

Secondary outcomes

  1. Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in SRD Part

    Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) in SRD part is presented.

    Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72, 96, 168 h after drug administration.

  2. Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in SRD Part

    Maximum measured concentration of BI 894416 in plasma (Cmax) in SRD part is presented.

    Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72, 96, 168 h after drug administration.

  3. Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) in Rel BA Part

    Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.

    Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.

  4. Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in Rel BA Part

    Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.

    Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.

  5. Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in Rel BA Part

    Maximum measured concentration of BI 894416 in plasma (Cmax) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.

    Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.

07

Results

Posted Mar 18, 2024

Participant flow

Single rising dose (SRD) part was designed as single-blind, partially randomized within dose groups, placebo-controlled, parallel-group design and relative bioavailability (rel BA) part was an open-label, randomized two-way crossover followed by a fixed sequence design in healthy volunteers.

Period 1
Participant flow — Period 1
MilestonePlacebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)BI 894416 10mg tb / 10mg PfOS / 40mg tbBI 894416 10mg PfOS / 10mg tb / 40mg tb
Started14666666666
Completed14666666666
Not completed0000000000
Period 2
Participant flow — Period 2
MilestonePlacebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)BI 894416 10mg tb / 10mg PfOS / 40mg tbBI 894416 10mg PfOS / 10mg tb / 40mg tb
Started0000000066
Completed0000000066
Not completed0000000000
Period 3
Participant flow — Period 3
MilestonePlacebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)BI 894416 10mg tb / 10mg PfOS / 40mg tbBI 894416 10mg PfOS / 10mg tb / 40mg tb
Started0000000066
Completed0000000066
Not completed0000000000

Outcome measures

PrimaryPercentage of Participants With Drug-related Adverse Events in SRD Part

Percentage of participants with drug-related adverse events (AEs) in SRD part. Percentages are calculated using total number of subjects per treatment as the denominator. Percentages were rounded up to 1 decimal places.

Time frame:
From drug administration until end of the trial, up to 17 days.
Reported as:
Number · Percentage of participants
Percentage of Participants With Drug-related Adverse Events in SRD Part
Percentage of participantsPlacebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)
Percentage of Participants With Drug-related Adverse Events in SRD Part0.00.00.033.316.70.016.716.7
SecondaryArea Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in SRD Part

Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) in SRD part is presented.

Time frame:
Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72, 96, 168 h after drug administration.
Reported as:
Geometric mean · nanomole (nmol) * hour (h) / Litre (L)
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in SRD Part
nanomole (nmol) * hour (h) / Litre (L)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in SRD Part345 ± 34.9640 ± 101.01470 ± 96.73270 ± 27.16020 ± 20.67210 ± 28.111400 ± 29.6
SecondaryMaximum Measured Concentration of BI 894416 in Plasma (Cmax) in SRD Part

Maximum measured concentration of BI 894416 in plasma (Cmax) in SRD part is presented.

Time frame:
Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72, 96, 168 h after drug administration.
Reported as:
Geometric mean · nanomole (nmol)/Litre (L)
Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in SRD Part
nanomole (nmol)/Litre (L)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)
Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in SRD Part55.4 ± 11.1161.0 ± 37.5352.0 ± 26.9527.0 ± 31.31170.0 ± 26.41240.0 ± 23.02130.0 ± 16.7
SecondaryArea Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) in Rel BA Part

Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.

Time frame:
Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.
Reported as:
Geometric mean · nanomole (nmol) * hour (h)/Litre (L)
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) in Rel BA Part
nanomole (nmol) * hour (h)/Litre (L)BI 894416 10 mg tb (T)BI 894416 10 mg PfOS (R)BI 894416 40 mg tb
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) in Rel BA Part941 ± 95.2853 ± 89.05870 ± 61.2
Statistical analysis
  • BI 894416 10 mg tb (T) vs BI 894416 10 mg PfOS (R) · Geometric mean (gmean) ratio (t/r) %: 110.31 · 90% CI 100.73 to 120.79To get, gMean ratio (T/R) and confidence interval, least square estimates of log-transformed PK endpoint for T and R were back transformed to original scale. Intra-individual geometric coefficient of variation (%) = 12.3.
SecondaryArea Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in Rel BA Part

Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.

Time frame:
Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.
Reported as:
Geometric mean · nanomole (nmol) * hour (h)/Litre (L)
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in Rel BA Part
nanomole (nmol) * hour (h)/Litre (L)BI 894416 10 mg tb (T)BI 894416 10 mg PfOS (R)BI 894416 40 mg tb
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in Rel BA Part975 ± 97.5879 ± 90.46060 ± 63.5
Statistical analysis
  • BI 894416 10 mg tb (T) vs BI 894416 10 mg PfOS (R) · Gmean ratio (t/r) %: 110.83 · 90% CI 101.20 to 121.38To get, gMean ratio (T/R) and confidence interval, least square estimates of log-transformed PK endpoint for T and R were back transformed to original scale. Intra-individual geometric coefficient of variation (%) = 12.3.
SecondaryMaximum Measured Concentration of BI 894416 in Plasma (Cmax) in Rel BA Part

Maximum measured concentration of BI 894416 in plasma (Cmax) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.

Time frame:
Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.
Reported as:
Geometric mean · nanomole (nmol)/Litre (L)
Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in Rel BA Part
nanomole (nmol)/Litre (L)BI 894416 10 mg tb (T)BI 894416 10 mg PfOS (R)BI 894416 40 mg tb
Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in Rel BA Part199 ± 39.5180 ± 53.41160 ± 39.2
Statistical analysis
  • BI 894416 10 mg tb (T) vs BI 894416 10 mg PfOS (R) · Gmean ratio (t/r) %: 110.46 · 90% CI 89.74 to 135.96To get, gMean ratio (T/R) and confidence interval, least square estimates of log-transformed PK endpoint for T and R were back transformed to original scale. Intra-individual geometric coefficient of variation (%) = 28.6.

Adverse events

Collected over For SRD part: From drug administration until end of the trial, up to 17 days. For rel BA part: From drug administration until end of the trial, up to 54 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Matching BI 894416 (SRD Part)0/14 (0%)0/14 (0%)3/14 (21.4%)
BI 894416 3 Milligram (mg) (SRD Part)0/6 (0%)0/6 (0%)2/6 (33.3%)
BI 894416 10 mg (SRD Part)0/6 (0%)0/6 (0%)2/6 (33.3%)
BI 894416 20 mg (SRD Part)0/6 (0%)0/6 (0%)5/6 (83.3%)
BI 894416 30 mg (SRD Part)0/6 (0%)0/6 (0%)2/6 (33.3%)
BI 894416 40 mg (SRD Part)0/6 (0%)0/6 (0%)2/6 (33.3%)
BI 894416 54 mg (SRD Part)0/6 (0%)0/6 (0%)1/6 (16.7%)
BI 894416 70 mg (SRD Part)0/6 (0%)0/6 (0%)2/6 (33.3%)
BI 894416 10 mg PfOS (R)0/12 (0%)0/12 (0%)4/12 (33.3%)
BI 894416 10 mg tb (T)0/12 (0%)0/12 (0%)3/12 (25%)
BI 894416 40 mg tb0/12 (0%)0/12 (0%)4/12 (33.3%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlacebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)BI 894416 10 mg PfOS (R)BI 894416 10 mg tb (T)BI 894416 40 mg tb
DiarrhoeaGastrointestinal disorders0/140/60/62/61/60/60/60/60/120/120/12
HeadacheNervous system disorders2/142/61/62/60/61/61/62/62/121/120/12
Abdominal painGastrointestinal disorders0/140/60/60/61/60/60/60/60/120/120/12
Salivary hypersecretionGastrointestinal disorders0/140/60/60/61/60/60/60/60/120/120/12
ConjunctivitisInfections and infestations0/140/60/60/60/60/60/61/60/120/120/12
NasopharyngitisInfections and infestations0/140/61/61/60/61/60/60/60/120/120/12
Respiratory tract infectionInfections and infestations0/140/61/60/60/60/60/60/60/120/120/12
RhinitisInfections and infestations0/140/60/60/60/60/61/60/60/120/120/12
Arthropod stingInjury, poisoning and procedural complications0/140/60/60/61/60/60/60/60/120/120/12
Back painMusculoskeletal and connective tissue disorders0/140/60/61/60/60/60/60/60/120/120/12

Baseline characteristics

Treated set (TS): This subject set included all subjects who received at least 1 dose of BI 894416 or placebo.

Age, Continuous
Age, Continuous(Years)Placebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)BI 894416 10mg tb / 10mg PfOS / 40mg tbBI 894416 10mg PfOS / 10mg tb / 40mg tbTotal
Mean33.8 ± 7.333.2 ± 7.333.5 ± 6.435.7 ± 7.133.7 ± 7.038.2 ± 6.334.3 ± 5.534.2 ± 9.131.7 ± 8.330.5 ± 6.933.9 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)BI 894416 10mg tb / 10mg PfOS / 40mg tbBI 894416 10mg PfOS / 10mg tb / 40mg tbTotal
Female00000000000
Male1466666666668
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)BI 894416 10mg tb / 10mg PfOS / 40mg tbBI 894416 10mg PfOS / 10mg tb / 40mg tbTotal
Hispanic or Latino10100000002
Not Hispanic or Latino1365666666666
Unknown or Not Reported00000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Matching BI 894416 (SRD Part)BI 894416 3 Milligram (mg) (SRD Part)BI 894416 10 mg (SRD Part)BI 894416 20 mg (SRD Part)BI 894416 30 mg (SRD Part)BI 894416 40 mg (SRD Part)BI 894416 54 mg (SRD Part)BI 894416 70 mg (SRD Part)BI 894416 10mg tb / 10mg PfOS / 40mg tbBI 894416 10mg PfOS / 10mg tb / 40mg tbTotal
American Indian or Alaska Native00000000000
Asian00000000000
Native Hawaiian or Other Pacific Islander00000000000
Black or African American00001000001
White1466656666667
More than one race00000000000
Unknown or Not Reported00000000000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Sep 2018, 10 months.

Results were first posted in Mar 2024, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2017
First posted
Oct 20, 2017
StartActual
Nov 2, 2017
Primary completionActual
Sep 10, 2018
CompletionActual
Sep 10, 2018
Results first posted
Mar 18, 2024
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03315936
Responsible party
Sponsor
First posted
Oct 20, 2017
Start date
Nov 2, 2017
Primary completion
Sep 10, 2018
Completion
Sep 10, 2018
Results posted
Mar 18, 2024
Last update
Mar 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 894416

Start the discussion